Prescription opioid analgesics rapidly change the human brain
Published online 2011 Apr 30.
1. Introduction
Opioid prescriptions have increased markedly in recent years, driven by a greater reliance on the potent analgesics for the treatment of chronic pain [18, 34]. Opioid analgesics are second only to lipid regulators as the most dispensed drug class in the United States [28].
Hydrocodone, a moderately-powerful opioid, was dispensed in the United States more than any other drug in 2008 – over 128 million times [27]. As opioid use rises, it becomes increasingly important that we better understand the neurological and behavioral effects of those drugs – especially given the known risks of opioid dependence, addiction, cognitive impairment, and hyperalgesia [7, 13, 14, 29, 43, 44].
Recently, Upadhyay and colleagues [55] demonstrated that
prescription opioid-dependent patients evidenced a specific morphologic abnormality in the neural reward-processing network. In their cross-sectional study of 10 dependent individuals and 10 age-matched controls, the researchers found decreased gray matter volume in the bilateral amygdala. The amygdala is a key reward-modulating structure that is known to underlie opioid-related addiction, dependence, and tolerance [23, 26, 33, 36]. The results of the Upadhyay et al., paper adds to existing animal literature showing that opioid exposure has a broad range of effects on the amygdala, including decreased mu-opioid receptor sensitivity [40], modulated GABAA receptor functioning [58], and modified glutamate receptor targeting
snip
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3138838/